Novel Elecsys NfL Test from Roche Gains CE Approval for Detecting MS Neuroinflammation

Roche announced that its Elecsys Neurofilament Light Chain (NfL) test has received CE mark approval for the detection of neuroinflammation in patients with relapsing remitting multiple sclerosis (RRMS). This innovative test represents a significant advancement in the management of MS, providing clinicians with a minimally invasive method to monitor the biological damage caused by the disease. By utilizing a straightforward blood test to measure NfL, a protein released during nerve cell injury, Elecsys NfL offers valuable insights into the neuroinflammation associated with multiple sclerosis. This development could facilitate more regular monitoring for a greater number of individuals living with the condition.

According to Precedence Research, the Neuroinflammation Market was valued at USD 8.60 billion in 2025 and is projected to grow from USD 9.53 billion in 2026 to approximately USD 23.81 billion by 2035, expanding at a CAGR of 10.90% from 2026 to 2035, driven by the increasing geriatric population with neuroinflammation.

Elecsys NfL Expands Access to MS Monitoring

Multiple sclerosis is a chronic condition that impacts over 2.9 million individuals globally. Timely and consistent monitoring of disease activity is essential for optimizing treatment; however, many patients encounter challenges in accessing routine evaluations, such as MRI scans, which are vital for the early detection of changes in their condition. The Elecsys NfL test offers an alternative perspective by measuring biological markers indicative of neuroaxonal damage, which reflect levels of neuroinflammation. This information enhances standard clinical assessments and MRI results, potentially facilitating earlier and more informed clinical management.

Standardized Blood Testing Reduces MRI Burden

Roche Diagnostics has announced that its newly approved Elecsys NfL test represents a significant advancement in the monitoring of adults with relapsing-remitting multiple sclerosis (RRMS). This blood-based test is intended to complement the resource-intensive MRI scans, thereby enhancing patient access to disease monitoring. Utilizing Roche’s cobas instruments, the test provides standardized and consistent results across various testing locations. With only a simple blood sample required, it can be collected locally, minimizing the necessity for patients to travel to specialized centers. Roche emphasizes that this test could facilitate more frequent monitoring for patients who face geographic, financial, or logistical challenges, ultimately supporting timely reassessment and more personalized disease management.

A recent report by Precedence Research highlights that the Neuroinflammation Market is benefiting from the rising innovation and clinical studies for neurodegenerative disorders.